EN DE
Watch ImmuneOnco Biopharms for free: we tell you when fair value or trend changes.
Data-driven stock valuation

ImmuneOnco Biopharms (1541) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of ImmuneOnco Biopharms stock HK$2.11, price HK$2.81, that is 24.8% below the price, quality 41 out of 100. Rating: overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China

IB ImmuneOnco Biopharms logo Thin data Nov 8, 2026

ImmuneOnco Biopharms

1541 · HK
Expensive, weak quality

Our calculation puts a fair price 25% below what the stock costs today.

Low debt
Quality 41/100
Mixed Growth (revenue 3y +197.8 %/yr in CNY)
Revenue last quarter 15% below a year ago.
Fair value HK$2.11 · Overvalued
Loss-making · -156.0% net margin (TTM)
Negative free cash flow
Trails peers (3/9)
Narrow moat 10/100 · thin data
Thin data
Watch ImmuneOnco Biopharms for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$31.05 HK$2.81 Fair Value HK$2.11 Sep 2023 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

38‑month range HK$2.81 – HK$31.05 · fair‑value band HK$1.39 – HK$2.63 · the HK$2.81 price screens above the HK$2.11 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow ImmuneOnco Biopharms in your weekly email

Every Wednesday you see whether ImmuneOnco Biopharms is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in China and the United States.

Show moreShow less

The company's core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma; Phase II clinical trial in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia; and Phase III clinical trial in combination with tislelizumab, targeting relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) patients who relapsed or progressed after the treatment of PD-1 inhibitors.

It also develops IMM0306 that is in Phase Ib/IIa clinical trial for the treatment of R/R CD20-positive B-cell non-Hodgkin lymphoma (B-NHL); IMM2510, which is in Phase Ib/IIa clinical trial to treat R/R soft tissue sarcoma; IMM27M that in Phase Ib/II clinical trial to treat solid tumors; and IMM2520, which is in Phase I clinical trial for solid tumors.

In addition, the company develops IMC-002 for treating autoimmune indications; IMC-001 for the treatment of atherosclerosis; IMM72; IMM7211b; IMM51, IMM38, IMM50, and IMM62 for solid tumors; and IMM40H for liquid/solid tumors.

It has license and collaboration agreement with Instil Bio, Inc. for the development of IMM2510 and IMM27M. ImmuneOnco Biopharmaceuticals (Shanghai) Inc. was incorporated in 2015 and is headquartered in Shanghai, China.

Stock analysis

ImmuneOnco Biopharms (1541) currently trades at HK$2.81, while our model-based Fair Value estimate is HK$2.11, 25% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: HK$1.39 (bear) to HK$2.63 (bull), the price of HK$2.81 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

ImmuneOnco Biopharms reported revenue of 150M CNY in FY2025 versus 13.8M CNY in FY2021, a compound +81.6%/yr. Reported net income was −213M CNY in FY2025.

Key figures

Market cap HK$1.2B (≈ $154M) Micro · P/S ratio 8.39 · Net margin −142% · Return on equity −40.1% · Return on assets (EBIT) −32.4% (5-year average) · Operating margin −378% · Revenue (TTM) 148M CNY · Revenue growth (YoY) −15.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 66% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −25%, 1541 screens richer than that median.

Fair Value models

Bear HK$1.39 Fair Value HK$2.11 Bull HK$2.63
Price HK$2.81 · Downside -24.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) HK$1.39 HK$2.11 HK$2.63 55
All 1 models by family
Asset-Based
NCAV (Graham) HK$1.39 HK$2.11 HK$2.63 55

Open the full fair value analysis →

Quality Score breakdown

Overall quality 41/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 5
How much profit the company makes from its sales and capital
Quality Growth 76
Are margins and returns getting better?
Cashflow 9
Do the profits arrive as real cash?
Financial strength 72
Debt, balance sheet and risk of trouble
Investment 84
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 12
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 27
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+102.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+197.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,524.2% (2021) → −144.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

1541 screens overvalued: fair value 25% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare ImmuneOnco Biopharms with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 41 · Below median
Fair Value upside −24.8% · Above median
Profitability
Return on assets −19.4% · Below median
Net margin (12 months) −156.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −15.4% · Bottom 25%
Balance sheet
Debt / equity 0.03× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.30× · Cheaper than median
P/S (12 months) 6.98× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)98 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs 1541
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs 1541
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs 1541
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs 1541
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs 1541
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs 1541
argenx SE ARGX $927.21 $908.40 −2% vs 1541
CSL Limited CSL A$200.77 A$183.04 −9% vs 1541
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs 1541
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs 1541

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ImmuneOnco Biopharms: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "ImmuneOnco Biopharms Fair Value". https://www.fairvalue-calculator.com/stock/1541

Frequently asked questions

Is ImmuneOnco Biopharms (1541) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of HK$2.11 versus a price of HK$2.81, about 25% lower (overvalued).
What is the fair value of 1541?
Our model-based fair value for ImmuneOnco Biopharms is HK$2.11 (as of Nov 8, 2026), built from audited fundamentals. The current price: HK$2.81.
What is the quality score of 1541?
ImmuneOnco Biopharms has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ImmuneOnco Biopharms (1541)?
Our model-based price target is the fair value of HK$2.11 (as of Nov 8, 2026) from 1 valuation models. Cautious scenario HK$1.39, optimistic scenario HK$2.63. It is a calculation from audited fundamentals, not an analyst target.
What is the ImmuneOnco Biopharms stock forecast for 2026?
Our models put fair value at HK$2.11, about 25% lower versus a price of HK$2.81 (overvalued). Cautious scenario HK$1.39, optimistic scenario HK$2.63. The calculation is refreshed regularly with new filings.
What is the revenue of ImmuneOnco Biopharms (1541)?
ImmuneOnco Biopharms reported trailing-twelve-month revenue of about 148M CNY (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of ImmuneOnco Biopharms (1541)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ImmuneOnco Biopharms it is HK$2.11 per share (as of Nov 8, 2026), against a price of HK$2.81. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is ImmuneOnco Biopharms stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 1541 trades above its calculated fair value: price HK$2.81, fair value HK$2.11, a gap of about −25% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1541?
No. The price is what the market pays today (HK$2.81); the fair value is what the company's own numbers justify (HK$2.11). For ImmuneOnco Biopharms the two are HK$0.6950 per share apart. That gap is exactly why we show both numbers side by side.
How much is ImmuneOnco Biopharms worth?
The market values ImmuneOnco Biopharms at about HK$1.2B (market capitalisation, as of Nov 8, 2026). Per share that is HK$2.81; our models calculate a fair value of HK$2.11 per share.
What do the bullish and bearish scenarios say about 1541?
Our models span a range for ImmuneOnco Biopharms: cautious scenario HK$1.39, base HK$2.11, optimistic HK$2.63 per share (as of Nov 8, 2026, price HK$2.81). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ImmuneOnco Biopharms (1541)?
Balance-sheet figures for ImmuneOnco Biopharms (as of Nov 8, 2026): return on equity −40.1%, debt of 0.03 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is 1541 from its 52-week high?
ImmuneOnco Biopharms trades at HK$2.81, about 66% below its 52-week high of HK$8.27 and at the low of HK$2.81 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of HK$2.11 is for.
Which stocks are comparable to ImmuneOnco Biopharms?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ImmuneOnco Biopharms stock attractive at the current price?
The data as of Nov 8, 2026: price HK$2.81, calculated fair value HK$2.11 (−25%), Quality Score 41/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1541 calculated?
We run ImmuneOnco Biopharms through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of HK$2.11 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. ImmuneOnco Biopharms itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ImmuneOnco Biopharms (1541)?
The closing price on Nov 6, 2026 was HK$2.81. Our model-based fair value is HK$2.11, about 25% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ImmuneOnco Biopharms right now?
The price sits above even our optimistic bull case (HK$2.63). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (HK$1.39 to HK$2.63) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of ImmuneOnco Biopharms

How large is the market capitalisation of ImmuneOnco Biopharms (1541)?
The market capitalisation of ImmuneOnco Biopharms is HK$1.2B (≈ $154M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ImmuneOnco Biopharms (1541)?
The price-to-sales ratio of ImmuneOnco Biopharms is 8.39 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of ImmuneOnco Biopharms (1541)?
The net margin of ImmuneOnco Biopharms is −142% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ImmuneOnco Biopharms (1541)?
The return on equity (ROE) of ImmuneOnco Biopharms is −40.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ImmuneOnco Biopharms (1541)?
On an EBIT basis the return on assets of ImmuneOnco Biopharms is −32.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ImmuneOnco Biopharms (1541)?
The operating margin of ImmuneOnco Biopharms is −378% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ImmuneOnco Biopharms (1541)?
Revenue at ImmuneOnco Biopharms is growing −15.4% versus a year earlier (3y avg +198%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does ImmuneOnco Biopharms (1541) generate?
The free cash flow of ImmuneOnco Biopharms is −197M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does ImmuneOnco Biopharms (1541) hold?
ImmuneOnco Biopharms holds more cash than debt, 452M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch ImmuneOnco Biopharms in the live analysis

One click puts ImmuneOnco Biopharms on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.